Log In
Print this Print this

Biosimilar bevacizumab (AP017)

  Manage Alerts
Collapse Summary General Information
Company Aprogen Inc.
DescriptionBiosimilar of bevacizumab, a humanized mAb against VEGF
Molecular Target Vascular endothelial growth factor (VEGF)
Mechanism of ActionVascular endothelial growth factor (VEGF) inhibitor; Antibody; Biosimilar
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentDiscovery
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today